NEW YORK, April 25, 2012 /PRNewswire/ -- Carl C. Icahn today announced that his affiliates had voluntarily dismissed their lawsuit against Amylin Pharmaceuticals which had sought an extension of the deadline to nominate directors at the 2012 annual meeting of shareholders. Mr. Icahn released the following statement:
The decision to discontinue our lawsuit seeking to extend the director nomination deadline was the result of discussions I had with Daniel Bradbury, Amylin’s chief executive officer, that we agreed would not be publicly disclosed.
Mr. Icahn reiterated that he continues to strongly believe that the company should be sold at this time.
SOURCE Carl C. Icahn
